73rd Session of the WHO Regional Committee for Europe – Statement on agenda item 11 – Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
The European Association for the Study of the Liver welcomes the Fourteenth General Programme of Work 2025-2028 (GPW14) consultation document and would like to draw attention to the importance of recognising the burden of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD) and integrating the disease into the development of the GPW14.